Galecto Announces Key Additions to Leadership Team
Galecto, Inc. (GLTO)
Company Research
Source: GlobeNewswire
Deep hematology/oncology drug development experience added with the appointment of Sherwin Sattarzadeh as Chief Operating Officer and Becker Hewes as Chief Medical Officer DMR-001, a potentially best-in-class mutant calreticulin (“mutCALR”) targeting monoclonal antibody, on track for IND submission in mid-2026 with anticipated first-in-human dosing via subcutaneous administration Cash balance, including $285 million raised in November 2025 PIPE, provides financial runway into 2029 to support multiple data milestones, including Ph1 clinical proof-of-concept data for DMR-001 anticipated in 2027 BOSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (“Galecto” or the “Company”), a biotechnology company developing novel therapeutics to redefine the treatment paradigm for people living with blood cancers, including mutant calreticulin (“mutCALR”) myeloproliferative neoplasms (“MPN”), today announced the appointment of Sherwin Sattarzadeh, former Chief Business Officer of Blueprint Me
Show less
Read more
Impact Snapshot
Event Time:
GLTO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GLTO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GLTO alerts
High impacting Galecto, Inc. news events
Weekly update
A roundup of the hottest topics
GLTO
News
- Galecto Highlights Key Strategic Priorities and Anticipated 2026 Milestones [Yahoo! Finance]Yahoo! Finance
- Galecto Highlights Key Strategic Priorities and Anticipated 2026 MilestonesGlobeNewswire
- Galecto (NASDAQ:GLTO) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.MarketBeat
- Galecto (NASDAQ:GLTO) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $46.00 price target on the stock.MarketBeat
- Galecto appoints former Blueprint Medicines executives as COO and CMO [Seeking Alpha]Seeking Alpha
GLTO
Sec Filings
- 1/12/26 - Form SCHEDULE
- 1/12/26 - Form SCHEDULE
- 1/12/26 - Form 8-K
- GLTO's page on the SEC website